Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 149

1.

Is testosterone treatment good for the prostate? Study of safety during long-term treatment.

Feneley MR, Carruthers M.

J Sex Med. 2012 Aug;9(8):2138-49. doi: 10.1111/j.1743-6109.2012.02808.x.

PMID:
22672563
2.

Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.

Coward RM, Simhan J, Carson CC 3rd.

BJU Int. 2009 May;103(9):1179-83. doi: 10.1111/j.1464-410X.2008.08240.x.

4.

Outcomes of Prostate Biopsy in Men with Hypogonadism Prior or During Testosterone Replacement Therapy.

Shoskes DA, Barazani Y, Fareed K, Sabanegh E Jr.

Int Braz J Urol. 2015 Nov-Dec;41(6):1167-71. doi: 10.1590/S1677-5538.IBJU.2014.0528.

6.

Higher sex hormone-binding globulin and lower bioavailable testosterone are related to prostate cancer detection on prostate biopsy.

García-Cruz E, Carrión Puig A, García-Larrosa A, Sallent A, Castañeda-Argáiz R, Piqueras M, Ribal MJ, Leibar-Tamayo A, Romero-Otero J, Alcaraz A.

Scand J Urol. 2013 Aug;47(4):282-9. doi: 10.3109/00365599.2012.747562.

PMID:
23181478
7.

The effect of testosterone replacement therapy on prostate cancer: a systematic review and meta-analysis.

Cui Y, Zong H, Yan H, Zhang Y.

Prostate Cancer Prostatic Dis. 2014 Jun;17(2):132-43. doi: 10.1038/pcan.2013.60. Review.

PMID:
24445948
8.

Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial.

Muller RL, Gerber L, Moreira DM, Andriole G, Castro-Santamaria R, Freedland SJ.

Eur Urol. 2012 Nov;62(5):757-64. doi: 10.1016/j.eururo.2012.05.025.

PMID:
22658758
9.

Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial.

Marks LS, Mazer NA, Mostaghel E, Hess DL, Dorey FJ, Epstein JI, Veltri RW, Makarov DV, Partin AW, Bostwick DG, Macairan ML, Nelson PS.

JAMA. 2006 Nov 15;296(19):2351-61.

PMID:
17105798
10.

Low testosterone bioavailability is related to prostate cancer diagnose in patients submitted to prostate biopsy.

García-Cruz E, Huguet J, Piqueras M, Márquez MP, Peri L, Izquierdo L, Franco A, Alvarez-Vijande R, Ribal MJ, Alcaraz A.

World J Urol. 2012 Jun;30(3):361-5. doi: 10.1007/s00345-011-0741-9.

PMID:
21833558
11.

Testosterone treatment in hypogonadal men: prostate-specific antigen level and risk of prostate cancer.

Guay AT, Perez JB, Fitaihi WA, Vereb M.

Endocr Pract. 2000 Mar-Apr;6(2):132-8.

PMID:
11421528
12.

Prostate cancer risk in testosterone-treated men.

Raynaud JP.

J Steroid Biochem Mol Biol. 2006 Dec;102(1-5):261-6. Review.

PMID:
17113983
13.

[Testosterone and the prostate].

Sperling H, Rossi R, Lümmen G, Rübben H.

Urologe A. 2004 Sep;43(9):1092-6. Review. German.

PMID:
15368045
14.

Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.

Faria EF, Carvalhal GF, dos Reis RB, Tobias-Machado M, Vieira RA, Reis LO, Nogueira L, Machado RD, Freitas CH Jr, Magnabosco WJ, Mauad EC, Carvalho AL.

BJU Int. 2012 Dec;110(11 Pt B):E653-7. doi: 10.1111/j.1464-410X.2012.11398.x.

16.

Testosterone replacement therapy in men with prostate cancer: a time-varying analysis.

Kaplan AL, Lenis AT, Shah A, Rajfer J, Hu JC.

J Sex Med. 2015 Feb;12(2):374-80. doi: 10.1111/jsm.12768.

PMID:
25496237
17.

Retrospective investigation of testosterone undecanoate depot for the long-term treatment of male hypogonadism in clinical practice.

Conaglen HM, Paul RG, Yarndley T, Kamp J, Elston MS, Conaglen JV.

J Sex Med. 2014 Feb;11(2):574-82. doi: 10.1111/jsm.12401.

PMID:
24279472
18.

Androgen therapy: testing before prescribing and monitoring during therapy.

Katz A, Katz A, Burchill C.

Can Fam Physician. 2007 Nov;53(11):1936-42.

19.

Testosterone therapy for men at risk for or with history of prostate cancer.

Morgentaler A.

Curr Treat Options Oncol. 2006 Sep;7(5):363-9. Review.

PMID:
16904053
20.

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology..

Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Review.

PMID:
24321502
Items per page

Supplemental Content

Support Center